I. Description of cases
Patient, male, aged 32, admitted for five days for fever, cough, cough and chest pain. Five days ago, the patient showed no visible incendiary heat, with a temperature of up to 39.8 °C, accompanied by cold warfare, an irritating cough, a rusty cough, a chest ache on the right, and an increase in deep breath and cough. The body temperature can decline briefly after taking a self-inflammation pill but then rises. Used to be healthy, drug-free allergy.
Hospitalisation: Body temperature 39.2°C, pulse 102/min, breathing 22/min, blood pressure 120/80 mmHg. Acute heat appearances, reduced right-hand respiratory activity, increased speech tremors, pronunciation, smell and bronchial breathing. Laboratory examinations: regular blood platinum count of 15 x 109/L with a neutral particle count of 85%; C reaction protein (CRP) 120 mg/L; calcium reduction (PCT) 0.5g/mL. The X-ray of the chest shows a large demography of the right lung and considers large leaf pneumonia.
II. The process of treatment
After admission to hospital, the initial diagnosis was for pneumococcal pneumococcal infection, which is considered to be high. After bacterium development and drug-sensitization tests have been carried out with swirling specimens, experientially selected head fursin is used for anti-infection treatment. Furan is used for intravenous dripping at 1.5 g each, every 8 hours. Treatment is also provided for the symptoms, including deheating, coughing and stinging.
On the third day of the treatment, the temperature of the patient began to decline and fluctuated at about 38°C, with a slight reduction in cough and chest pain. The treatment continues with the use of head fursynthesis, and by the fifth day, the patient ‘ s body temperature has largely returned to normal, with reduced coughing and a marked reduction in chest pain. Review of blood patterns: white cell count 10 x 109/L, 70 per cent of neutral particle cells; CRP 60mg/L.
On the seventh day of the treatment, the patient ‘ s symptoms were further improved, with no fever, a slight cough and a small amount of white. Cultivation results in the form of pneumococcus, which is highly sensitive to head fur. The consolidation of the treatment continued for three days and the clinical symptoms of the patient completely disappeared, with a review of the chest X-ray showing a clear absorption of the right oscillation of the right lung. Throughout the treatment, there was no adverse medical response.
III. Discussion
(i) The pharmacological properties and mechanisms of operation of hair fracking
Difrosin is a second-generation antibiotic, antibacterial activity is similar to or slightly worse than that of the first-generation antibacteria, but more antibacterial activity is found in the gland cacteria. Its mechanism of action is primarily microbicide by inhibiting the synthesis of bacterial cell walls. For common pneumocococcal strains, such as pneumocococcus, PFC can effectively inhibit growth and reproduction. It combines penicillin with proteins, hinders the synthesis of cell glucose, and causes bacterial cell walls to fail, leading to bacterial cell rupture and death.
(ii) Basis of choice of treatment
In the treatment of pneumonia, the early empirical choice of antibiotics is crucial. Given the clinical behaviour of patients (typical symptoms such as high heat, cough rust, chest pain) and laboratory tests (high white and neutral particle cell rise, CRP rise, etc.), there is a high level of suspicion of pneumocococcal infections. The pneumococcal streptococcus is relatively active and safe and can be one of the drugs of choice while waiting for the results. Its extensive antibacterial spectroscopy can also cover other gland cactus infections that may be combined and reduce the risk of treatment delays.
(iii) Treatment impact assessment
In this case, the efficacy of the treatment of hair fracking is significant. The rapid decline in the patient ‘ s post-treatment temperature, the gradual reduction of symptoms and the consequent decrease in inflammation indicators (white cells, CRPs, etc.) suggest that the hexafluorine is effective in controlling the inflammation response to pneumonia streptocyccus infections. At the same time, the patient did not react negatively throughout the treatment, reflecting the good tolerance of the head fur. Furthermore, subsequent stinging results have confirmed the sensitivity of PFC to the pathogen of the patient and have further supported the correctness of the treatment programme.
(iv) Experience and inspiration
This case has provided some experience for the treatment of pneumoconiosis. In clinical practice, experiential anti-infection treatment based on clinical performance and preliminary examination should be provided in a timely manner for patients suspected of pneumonia pneumonia. Headfurcin, as a commonly used and effective antibiotics, can play an important role in appropriate circumstances. At the same time, changes in patients ‘ symptoms, signs and laboratory indicators are closely observed in the treatment process, and treatment programmes are adjusted in a timely manner, based on the results of saliva and pharmacological tests, in order to improve treatment effectiveness and reduce the incidence of complications. In addition, comprehensive treatment, including support for the treatment of cases of pneumoconiosis, cannot be ignored and can help people to recover more quickly.
In general, hexafluoride has good potential for application in the treatment of folate pneumonia infection, but it needs to be used reasonably in a clinical context.
